Tafenoquine in Patients With Mild to Moderate COVID-19
Study sponsor: 60 Degrees Pharmaceuticals LLC
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-06-30Actual
Enrollment · participants86Actual
Source updated2025-01-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.